Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
16 studies found for:    GCK
Show Display Options
Rank Status Study
1 Unknown  Liraglutide Actions on the Liver: Effects on Glucose Phosphorylation
Condition: Type 2 Diabetes
Intervention: Drug: Liraglutide
2 Completed Using Pharmacogenetics to Improve Treatment in Early-onset Diabetes
Condition: Diabetes
Intervention: Other: patient care pathway
3 Terminated
Has Results
A Study of LY2599506 (Oral Agent Medication: Glucokinase Activator 1) in Type 2 Diabetes Mellitus
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: LY2599506;   Drug: Glyburide;   Drug: Placebo
4 Completed Drug-Drug Interaction Study of Glucokinase Activator HMS5552 and Metformin in T2DM
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Metformin;   Drug: HMS5552
5 Recruiting Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes
Condition: Maturity-Onset Diabetes of the Young
Intervention: Other: insulin therapy
6 Unknown  The Effect of ß-cell Specific Glucokinase Mutation on Glucose Homeostasis and Insulin Secretion in a MODY-2 Family
Condition: MODY-2 Diabetes
Intervention: Other: OGTT
7 Completed A Study of LY2608204 in Patients With Type 2 Diabetes
Condition: Diabetes Mellitus, Type 2
Intervention: Drug: LY2608204
8 Completed A Study to Compare Two Forms of LY2608204 in Healthy People
Condition: Healthy Volunteers
Interventions: Drug: LY2608204 Reference;   Drug: LY2608204 Test
9 Completed Add Glucokinase Activator to Target A1c
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: TTP399 400 mg;   Drug: TTP399 800 mg;   Drug: Sitagliptin 100 mg;   Drug: Placebo
10 Terminated
Has Results
A Study of LY2599506 in Patients With Type 2 Diabetes
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo;   Drug: LY2599506
11 Completed Pathophysiological Implications of the Incretin Hormones in Maturity Onset of Diabetes of the Young (MODY)
Condition: Maturity-onset Diabetes of the Young
Interventions: Other: Oral Glucose Tolerance Test (OGTT);   Other: iso glycaemic intravenous (iv) glucose infusion (IIGI);   Dietary Supplement: Meal test;   Other: Sitagliptin;   Other: Incretin effect on sulphonyl urea treatment
12 Completed A Safety Study of ARRY-403 in Patients With Type 2 Diabetes
Condition: Type 2 Diabetes
Interventions: Drug: ARRY-403, glucokinase activator; oral;   Drug: Placebo; oral
13 Completed A Safety Study of ARRY-403 in Patients With Type 2 Diabetes
Condition: Type 2 Diabetes
Interventions: Drug: ARRY-403, glucokinase activator; oral;   Drug: Placebo; oral
14 Suspended A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of Oral ZYGK1 in Healthy Volunteers
Condition: Diabetes
Interventions: Drug: ZYGK1;   Drug: Placebo
15 Completed Predisposition Genes in Monogenic Diabetes (DIAMONO)
Condition: Non Autoimmune Monogenic Diabetes
Intervention: Genetic: blood sample
16 Completed Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HMS5552 in Patients With Type 2 Diabetes
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: HMS5552;   Drug: Placebo

Indicates status has not been verified in more than two years